Pleurisy Market Analysis

ID: MRFR/HC/1179-HCR

200 Pages

Rahul Gotadki

February 2026

Pleurisy Market Research Report By Type (Acute Pleurisy, Chronic Pleurisy, Recurrent Pleurisy), By Diagnosis Method (Physical Examination, Imaging Tests, Laboratory Tests), By Treatment Type (Medication, Surgical Procedures, Therapeutic Procedures), By End User (Hospitals, Clinics, Home Care) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Pleurisy Market Industry Landscape

The pleurisy market is a specialized phase within the healthcare industry, focusing on the analysis and remedy of pleurisy, an infection of the pleura surrounding the lungs. Pleurisy is often associated with underlying conditions such as infections, autoimmune issues, or lung sicknesses, making the market dynamic and multifaceted. Market dynamics are considerably inspired by epidemiological elements related to pleurisy. The occurrence of pleurisy is related to diverse scientific conditions, and know-how of these elements is critical for developing powerful diagnostic equipment and treatment techniques. Continuous improvements in diagnostic imaging technology pressure market dynamics. High-decision imaging techniques, which include chest X-rays, computed tomography (CT) scans, and ultrasound, play a pivotal function in diagnosing pleurisy, enabling healthcare experts to visualize pleural inflammation and check its severity. Pleuroscopy, an endoscopic procedure for analyzing the pleural cavity, impacts market dynamics. This minimally invasive method permits direct visualization, biopsy, and healing interventions, providing treasured diagnostic records and permitting centered remedies for pleurisy. Adherence to regulatory standards is vital in shaping market dynamics, especially concerning diagnostic accuracy. Diagnostic equipment and strategies for pleurisy must meet stringent regulatory requirements to ensure their protection, efficacy, and reliability in scientific exercise. Patient education and focus campaigns make contributions to market dynamics. Initiatives focused on educating each healthcare professional and the general public about the signs and symptoms, symptoms, and chance elements of pleurisy, goal to promote early reputation, well-timed intervention, and improved patient consequences. Differential prognosis challenges are a key attention in market dynamics. Pleurisy stocks symptoms with diverse respiration and cardiac situations, necessitating unique diagnostic tools and algorithms to differentiate pleuritic reasons as they should be. Pleurisy related to autoimmune disorders influences market dynamics. Immunomodulatory remedies, together with sickness-modifying antirheumatic tablets (DMARDs) and biologics, play a role in handling autoimmune-related pleurisy and addressing the underlying immune machine disorder. Global efforts to expand the right of entry to to healthcare services impact market dynamics. Collaboration between healthcare groups, producers, and policymakers contributes to making diagnostic tools and remedies for pleurisy to be had in numerous areas, addressing worldwide fitness disparities. The integration of telemedicine and far-off consultations is a developing trend in market dynamics. Telehealth systems allow healthcare experts to remotely evaluate patients with pleuritic signs and symptoms, facilitating timely consultations and lowering the need for in-man or woman visits. Environmental issues, inclusive of air quality and occupational exposures, are rising elements in market dynamics. Efforts to address environmental factors contributing to breathing fitness issues, such as pleurisy, align with broader attention on preventive healthcare.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Pleurisy Market as of 2024?

The overall market valuation was 0.56 USD Billion in 2024.

What is the projected market size for the Pleurisy Market in 2035?

The projected valuation for the Pleurisy Market in 2035 is 1.192 USD Billion.

What is the expected CAGR for the Pleurisy Market during the forecast period 2025 - 2035?

The expected CAGR for the Pleurisy Market during the forecast period 2025 - 2035 is 7.11%.

Which companies are considered key players in the Pleurisy Market?

Key players in the Pleurisy Market include Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG, Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson, and Gilead Sciences, Inc.

What are the market segments for Pleurisy based on type?

The market segments for Pleurisy based on type include Acute Pleurisy, Chronic Pleurisy, and Recurrent Pleurisy.

What were the valuations for Acute Pleurisy in 2024 and its projected value in 2035?

The valuation for Acute Pleurisy was 0.2 USD Billion in 2024 and is projected to reach 0.4 USD Billion in 2035.

How does the market for Chronic Pleurisy compare between 2024 and 2035?

Chronic Pleurisy had a valuation of 0.18 USD Billion in 2024, with a projected increase to 0.36 USD Billion by 2035.

What are the primary diagnosis methods used in the Pleurisy Market?

Primary diagnosis methods in the Pleurisy Market include Physical Examination, Imaging Tests, and Laboratory Tests.

What is the projected market value for Imaging Tests in 2035?

The projected market value for Imaging Tests in 2035 is 0.5 USD Billion.

What treatment types are available in the Pleurisy Market?

Treatment types available in the Pleurisy Market include Medication, Surgical Procedures, and Therapeutic Procedures.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future analysis, the Pleurisy Market Size was estimated at 0.56 USD Billion in 2024. The Pleurisy industry is projected to grow from USD 0.5998 Billion in 2025 to USD 1.192 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.11% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Pleurisy Market is experiencing notable advancements and shifts driven by technological innovations and changing healthcare dynamics.

North America remains the largest market for pleurisy treatments, driven by advanced healthcare infrastructure and high expenditure.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing healthcare access and rising awareness.
Acute pleurisy continues to dominate the market, while chronic pleurisy is witnessing rapid growth due to evolving treatment approaches.
Key market drivers include the increasing incidence of respiratory diseases and advancements in treatment modalities, which are shaping the market landscape.

Market Size & Forecast

2024 Market Size	0.56 (USD Billion)
2035 Market Size	1.192 (USD Billion)
CAGR (2025 - 2035)	7.11%
Largest Regional Market Share in 2024	North America

Major Players

Pfizer Inc (US), Bristol-Myers Squibb Company (US), Novartis AG (CH), Roche Holding AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Johnson & Johnson (US), Gilead Sciences, Inc. (US)

Market Trends

The Pleurisy Market is currently experiencing a notable evolution, driven by a combination of factors including advancements in diagnostic techniques and an increasing awareness of respiratory diseases. The rise in healthcare expenditure across various regions appears to facilitate the development of innovative treatment options, which may enhance patient outcomes. Furthermore, the growing prevalence of conditions that lead to pleurisy, such as pneumonia and autoimmune disorders, suggests a potential increase in demand for effective therapies. As healthcare systems adapt to these challenges, the Pleurisy Market is likely to witness a shift towards more personalized and targeted treatment approaches. In addition, the integration of telemedicine and digital health solutions into the management of pleurisy is becoming increasingly relevant. This trend indicates a transformation in how patients access care and receive follow-up consultations. The emphasis on patient-centered care, coupled with the ongoing research into novel pharmacological agents, may further shape the landscape of the Pleurisy Market. Overall, the market appears poised for growth, with stakeholders focusing on enhancing treatment efficacy and improving patient quality of life.

Advancements in Diagnostic Techniques

Recent innovations in imaging and laboratory testing are enhancing the accuracy of pleurisy diagnoses. These advancements enable healthcare providers to identify underlying causes more effectively, which may lead to timely and appropriate treatment interventions.

Rise of Telemedicine

The increasing adoption of telemedicine is transforming patient interactions in the Pleurisy Market. This trend allows for remote consultations and follow-ups, improving access to care and potentially leading to better management of pleurisy symptoms.

Focus on Personalized Medicine

There is a growing emphasis on personalized treatment strategies within the Pleurisy Market. Tailoring therapies to individual patient profiles may improve treatment outcomes and enhance overall patient satisfaction.

Pleurisy Market Market Drivers

Rising Healthcare Expenditure

The upward trend in healthcare expenditure across various regions appears to be a significant factor influencing the Pleurisy Market. Increased funding for healthcare services often translates into better access to diagnostic tools and treatment options for pleurisy. As governments and private sectors allocate more resources towards healthcare, the availability of advanced medical technologies and therapies is likely to improve. This trend may lead to enhanced patient care and outcomes, thereby driving demand within the Pleurisy Market. Additionally, as healthcare systems evolve to meet the needs of an aging population, the focus on respiratory health is expected to intensify, further contributing to market growth.

Integration of Telehealth Services

The integration of telehealth services into the healthcare system appears to be transforming the way pleurisy is managed. Telemedicine offers patients convenient access to healthcare professionals, which may facilitate timely consultations and follow-ups. This trend is particularly relevant for individuals living in remote areas where access to specialized care is limited. By enabling remote monitoring and consultations, telehealth could potentially increase the number of patients seeking treatment for pleurisy, thereby expanding the Pleurisy Market. Moreover, as healthcare systems continue to embrace digital solutions, investments in telehealth technologies are likely to rise, further enhancing the market landscape.

Advancements in Treatment Modalities

Innovations in treatment modalities for pleurisy, including the development of targeted therapies and minimally invasive procedures, seem to be propelling the Pleurisy Market forward. Recent advancements in medical technology have led to improved patient outcomes and reduced recovery times. For instance, the introduction of video-assisted thoracoscopic surgery (VATS) has revolutionized the management of pleural effusions, a common complication of pleurisy. This shift towards more effective treatment options may encourage healthcare providers to adopt these new modalities, thereby increasing the demand for related products and services. As a result, the Pleurisy Market is likely to witness a surge in investments aimed at research and development, further enhancing the therapeutic landscape.

Growing Awareness and Education Initiatives

The increasing awareness of pleurisy and its associated symptoms among both healthcare professionals and the general public appears to be a crucial driver for the Pleurisy Market. Educational campaigns aimed at improving knowledge about respiratory health are being implemented across various platforms. These initiatives may lead to earlier diagnosis and treatment of pleurisy, thereby increasing the demand for healthcare services. Furthermore, as patients become more informed about their conditions, they are more likely to seek medical attention, which could result in a higher incidence of diagnosed cases. This trend suggests that the Pleurisy Market may experience growth as healthcare providers respond to the rising demand for diagnostic and therapeutic options.

Increasing Incidence of Respiratory Diseases

The rising prevalence of respiratory diseases, including pneumonia and tuberculosis, appears to be a significant driver for the Pleurisy Market. As these conditions often lead to pleurisy, healthcare systems are increasingly focusing on early diagnosis and treatment. According to recent data, respiratory diseases account for a substantial portion of global morbidity and mortality, which may lead to heightened awareness and demand for pleurisy-related treatments. This trend suggests that healthcare providers are likely to invest more in diagnostic tools and therapeutic options, thereby expanding the Pleurisy Market. Furthermore, the aging population, which is more susceptible to respiratory ailments, could further exacerbate this trend, indicating a potential growth trajectory for the market.

Market Segment Insights

By Type: Acute Pleurisy (Largest) vs. Chronic Pleurisy (Fastest-Growing)

The Pleurisy Market exhibits diverse segment values, with Acute Pleurisy emerging as the largest segment due to its higher prevalence and immediate clinical importance. On the other hand, Chronic Pleurisy is gaining traction in the market, driven by rising awareness and advances in treatment options, leading to a notable increase in the patient base seeking management for long-term pleurisy conditions. Meanwhile, Recurrent Pleurisy remains a niche yet significant segment, typically influenced by underlying causes that warrant specific treatment approaches.

Pleurisy: Acute (Dominant) vs. Chronic (Emerging)

Acute Pleurisy represents the dominant force in the Pleurisy Market, characterized by sudden onset and often linked to infections or pneumonia, thus attracting immediate medical attention. Its management frequently involves prompt diagnosis and targeted therapies, driving its larger market share. Conversely, Chronic Pleurisy, though considered an emerging segment, is marked by inflammation that persists over longer periods, often necessitating continued treatment and follow-up care. This segment is experiencing swift growth due to expanding recognition of persistent pleuritic symptoms, advancements in disease management, and a greater focus on patient education, contributing to its rise in the overall market.

By Diagnosis Method: Physical Examination (Largest) vs. Imaging Tests (Fastest-Growing)

In the Pleurisy Market, the diagnosis methods are primarily categorized into Physical Examination, Imaging Tests, and Laboratory Tests. The Physical Examination remains the largest segment, as healthcare professionals typically conduct it first to assess symptoms and gather patient histories. Imaging Tests, however, are rapidly gaining traction as advancements in technology provide clearer insights into pleurisy, leading to their status as the fastest-growing segment in diagnostic methodologies.

Diagnosis Method: Physical Examination (Dominant) vs. Imaging Tests (Emerging)

Physical Examination is the dominant force in the Pleurisy Market, serving as the frontline approach for doctors to evaluate patients through direct assessment of symptoms. This method relies heavily on clinician expertise to interpret signs of inflammation and fluid accumulation. In contrast, Imaging Tests are emerging as critical tools in the diagnosis process. With ongoing technological advancements such as enhanced imaging techniques, these tests are increasingly preferred for their non-invasive nature and ability to provide precise visualizations of the pleural space, thus expediting diagnosis and treatment decisions.

By Treatment Type: Medication (Largest) vs. Surgical Procedures (Fastest-Growing)

In the Pleurisy market, the treatment types can be categorized primarily into Medication, Surgical Procedures, and Therapeutic Procedures. Medication remains the largest segment, as it encompasses a wide range of pharmaceutical options aimed at managing the symptoms and underlying causes of pleurisy. This segment's dominance is attributed to its accessibility and the continuous innovation in drug formulations that enhance patient outcomes. Surgical Procedures, while comparatively smaller, are experiencing significant growth due to advances in minimally invasive techniques and increasing awareness of the condition, making them the fastest-growing segment within the treatment options available.

Medication (Dominant) vs. Surgical Procedures (Emerging)

Medication for pleurisy encompasses various drug therapies including anti-inflammatories and pain relievers, which are pivotal in symptom management. This segment thrives on the ongoing advancements in pharmaceutical research, leading to new formulations that increase efficacy. The wide acceptance and use of these medications make it a dominant force in the market. Conversely, Surgical Procedures, which include interventions such as thoracentesis or pleurectomy, are emerging as a viable option particularly for cases resistant to medication. The trend towards less invasive surgeries aligns with patient preferences for quicker recovery and fewer complications, thus supporting growth in this segment.

By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

The Pleurisy Market showcases a diverse distribution among key end-user segments. Hospitals emerge as the dominant player, accounting for the largest share of market activity due to their extensive resources, specialized healthcare teams, and ability to manage complex cases. Clinics, on the other hand, are gaining ground, becoming an increasingly popular option for outpatient treatment and early intervention in pleurisy cases. Their convenience and accessibility make them a crucial part of the Pleurisy care continuum. Looking at growth trends, while hospitals maintain their significance, clinics are witnessing the fastest growth in the Pleurisy Market. This surge is driven by a growing preference for outpatient care, increased awareness of pleurisy symptoms, and an emphasis on early diagnosis. Home care services are also relevant but play a supporting role in providing specialized care for chronic pleurisy patients who cannot access hospitals or clinics easily. Overall, these trends indicate a shift towards more patient-centric care models within the Pleurisy Market.

Hospitals (Dominant) vs. Clinics (Emerging)

In the Pleurisy Market, hospitals represent the dominant end-user segment, characterized by their comprehensive medical facilities and a wide range of specialist services. They offer advanced diagnostic and treatment options for pleurisy cases, typically linked with pulmonary medicine and thoracic surgery departments. Hospitals' ability to perform extensive diagnostic imaging and provide critical care support makes them vital in managing severe cases. In contrast, clinics are emerging as an influential segment, appealing primarily to patients seeking early intervention and preventative care. Their patient-friendly approach, shorter wait times, and focus on outpatient services are appealing, driving their rapid growth. This shift represents a broader trend towards more accessible healthcare solutions, showing that clinics are becoming essential in the journey for pleurisy patients seeking timely treatment.

Get more detailed insights about Pleurisy Market Research Report-Forecast till 2035

Regional Insights

North America : Healthcare Innovation Leader

North America is the largest market for pleurisy treatments, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of respiratory diseases, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring timely access to innovative therapies. The United States leads the North American market, with a robust presence of key players such as Pfizer Inc., Merck & Co., and Johnson & Johnson. The competitive landscape is characterized by ongoing clinical trials and product launches aimed at improving treatment outcomes. Canada also contributes significantly, focusing on enhancing healthcare access and affordability for patients suffering from pleurisy.

Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for pleurisy, holding around 30% of the global share. The region benefits from a well-established healthcare system and increasing awareness of respiratory diseases. Regulatory frameworks, such as the European Medicines Agency's guidelines, are pivotal in expediting the approval of new treatments, thereby enhancing market growth. The rising geriatric population and lifestyle changes further drive demand for effective pleurisy therapies. Leading countries in Europe include Germany, France, and the UK, where major pharmaceutical companies like Novartis AG and Roche Holding AG are actively involved. The competitive landscape is marked by collaborations between public health organizations and private firms to develop innovative solutions. The presence of key players ensures a diverse range of treatment options for patients, contributing to overall market dynamism.

Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is witnessing rapid growth in the pleurisy market, driven by increasing healthcare expenditure and rising awareness of respiratory conditions. The region holds approximately 20% of the global market share, with countries like China and India leading the charge. Government initiatives aimed at improving healthcare access and affordability are significant growth catalysts, alongside a growing middle class that demands better healthcare services. China is the largest market in the region, with substantial investments in healthcare infrastructure and a focus on innovative treatment options. India follows closely, with a burgeoning pharmaceutical sector that includes key players like Gilead Sciences. The competitive landscape is evolving, with local companies increasingly collaborating with global firms to enhance treatment availability and affordability for patients suffering from pleurisy.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region represents an emerging market for pleurisy treatments, holding about 5% of the global share. The growth is hampered by challenges such as limited healthcare infrastructure and varying levels of access to medical services. However, increasing investments in healthcare and rising awareness of respiratory diseases present significant opportunities for market expansion. Regulatory bodies are beginning to implement frameworks to facilitate the introduction of new therapies. Countries like South Africa and the UAE are at the forefront of this market, with efforts to improve healthcare access and affordability. The competitive landscape is characterized by a mix of local and international players, with a focus on developing cost-effective treatment options. As healthcare systems evolve, the potential for growth in the pleurisy market is substantial, driven by both public and private sector initiatives.

Key Players and Competitive Insights

The Global Pleurisy Market has been experiencing a dynamic shift due to various factors including advancements in diagnostic techniques and therapeutic options available for patients. With a growing prevalence of pleural diseases and an increasing awareness about respiratory health, the competitive landscape is becoming more intricate as companies seek to position themselves effectively. Key players are focusing on innovation and expanding their product offerings to cater to unmet needs in the market.The race to enhance patient outcomes has triggered collaboration between pharmaceutical companies and healthcare professionals, while market analysis indicates a trend towards personalized medicine in treating conditions associated with pleurisy. This wave of evolution is likely fostering competitive strategies within the market, leading to a rich environment for new entrants as well as established firms aiming to bolster their market share.Pfizer has established a solid presence in the Global Pleurisy Market through its portfolio of treatments that address respiratory conditions.Known for its commitment to research and development, Pfizer leverages its extensive resources to create innovative therapies aimed at managing pleurisy and associated pleural diseases. The company’s strengths stem from its robust clinical trial capabilities and established relationships with healthcare providers, allowing it to effectively understand patient needs and market demands. Pfizer also has an expansive distribution network that facilitates accessibility to its products across various regions, enabling it to maintain a competitive edge by ensuring that its therapies are readily available to those who require them.The company’s focus on enhancing patient support programs further solidifies its reputation as a leader in the respiratory health sector.Merck and Co has also made significant strides in the Global Pleurisy Market, primarily through a range of pharmaceutical products aimed at treating respiratory diseases. The company is known for its comprehensive pipeline that includes both patented and generic drugs, reflecting its diverse approach to addressing pleurisy. Merck and Co's market presence is strengthened by its strategic mergers and acquisitions, which have broadened its capabilities and product offerings.The company invests heavily in research to develop new treatments that are not only effective but also improve patients' quality of life. Its strong emphasis on partnerships and collaborations with healthcare institutions further enhances its market position, enabling the company to effectively deliver innovative solutions. With a focus on clinical advancements and a commitment to patient-centered care, Merck and Co continues to be a prominent player in the Global Pleurisy Market.

Key Companies in the Pleurisy Market include

Industry Developments

Recent developments in the Global Pleurisy Market have been influenced significantly by advancements in pharmaceutical companies. In September 2023, AbbVie announced positive results from clinical trials for its new pleurisy treatment, potentially enhancing its market position. Pfizer has invested heavily in Research and Development initiatives focused on pleurisy-related therapies, aiming to improve patient outcomes. Meanwhile, Merck and Co. has been collaborating with various healthcare institutions to drive awareness and education regarding pleurisy management options.In terms of mergers and acquisitions, no significant activity has been reported impacting the companies of interest, such as Roche, Gilead Sciences, and AstraZeneca, within recent months.

Nonetheless, the cumulative valuation of these companies has shown an upward trend due to increasing global healthcare spending and the rising incidence of pleurisy conditions, which collectively elevate the demand for effective treatment solutions. Additionally, notable developments in the regulatory landscape, particularly in North America and Europe, have prompted further investments in the Global Pleurisy Market, encouraging innovation that could benefit patient care. Over the last two years, the focus on personalized medicine in pleurisy treatment has gained traction, reflecting a shift towards more tailored healthcare solutions for affected patients.

Future Outlook

Pleurisy Market Future Outlook

The Pleurisy Market is projected to grow at a 7.11% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies and increasing prevalence of respiratory diseases.

New opportunities lie in:

Development of telemedicine platforms for remote patient monitoring
Investment in AI-driven diagnostic tools for early detection
Expansion of targeted therapies to improve patient outcomes

By 2035, the Pleurisy Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Pleurisy Market Type Outlook

Acute Pleurisy
Chronic Pleurisy
Recurrent Pleurisy

Pleurisy Market End User Outlook

Hospitals
Clinics
Home Care

Pleurisy Market Treatment Type Outlook

Medication
Surgical Procedures
Therapeutic Procedures

Pleurisy Market Diagnosis Method Outlook

Physical Examination
Imaging Tests
Laboratory Tests

Report Scope

MARKET SIZE 2024	0.56(USD Billion)
MARKET SIZE 2025	0.5998(USD Billion)
MARKET SIZE 2035	1.192(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.11% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Pfizer Inc (US), Bristol-Myers Squibb Company (US), Novartis AG (CH), Roche Holding AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Johnson & Johnson (US), Gilead Sciences, Inc. (US)
Segments Covered	Type, Diagnosis Method, Treatment Type, End User, Regional
Key Market Opportunities	Advancements in diagnostic technologies enhance early detection and treatment options in the Pleurisy Market.
Key Market Dynamics	Rising prevalence of pleurisy drives demand for innovative treatment options and enhances competitive dynamics among pharmaceutical companies.
Countries Covered	North America, Europe, APAC, South America, MEA